Eli Lilly Vs. Merck: One is a No
Eli Lilly (LLY) reported Q2 revenue of $23B, up 48% YoY, driven by Mounjaro and Zepbound. Merck (MRK) saw 5% growth to $16.6B, with KEYTRUDA nearing peak penetration. Lilly raised FY2026 guidance to $85-87B and boasts an 86% gross margin. Merck's strategy focuses on new drugs like Lipvendra and WINREVAIR.
How this was made
The 30-second read
Why it matters
Earnings beats and guidance lifts for Lilly may trigger buying pressure, while Merck’s charge could cause a pullback.
Market read
Both companies are major constituents of the healthcare sector; their earnings diverge, influencing sector rotation.
What to watch
Potential supply constraints for Lilly’s new oral GLP‑1 and regulatory timelines for Merck’s PCSK9 program.
Background
The article compares Eli Lilly’s rapid GLP‑1 driven growth to Merck’s restructuring around KEYTRUDA and new PCSK9 assets.
Ticker impact
Eli Lilly reported Q2 revenue of $22.97 billion, up 47.7% YoY, and raised FY2026 revenue guidance to $85‑$87 billion.
Potential price appreciation in the near term as investors re‑price higher growth expectations.
Revenue growth of 48% and a sizable guidance increase are material for a large‑cap pharma stock.
Merck posted Q2 revenue of $16.6 billion, up 5% YoY, and disclosed a $5.7 billion acquisition charge leading to a loss.
Limited upside; possible short‑term downside as the market digests the charge.
Growth is modest and the acquisition charge offsets earnings, creating mixed signals.
Market effects
Highlights divergent trajectories in the pharma sector: strong GLP‑1 growth for Lilly versus a restructuring phase for Merck.
U.S. large‑cap healthcare indices may see a tilt toward growth‑oriented stocks.
Sets a benchmark for biotech and oncology pipelines worldwide.
Counterpoint
Merck’s lower valuation and dividend yield could attract value‑oriented investors despite the acquisition charge.
Key entities
- companyEli Lilly
Pharmaceutical company reporting strong Q2 results and raised guidance.
- companyMerck
Pharmaceutical company reporting modest Q2 growth and a large acquisition charge.
